Compare Merck & Co., Inc. (MRK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Veritone Inc — how do they compare? Merck & Co., Inc. trades at $133.68 (market cap $321.77B), while Veritone Inc trades at $1.54 (market cap $138.04M). The key difference: Merck & Co., Inc. is far larger — about 2331× Veritone Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| MRK | VERI | |
|---|---|---|
Market Cap | $321.77B | $138.04M |
Sector | Health | Technology |
52-Week High | $131.84 | $8.39 |
52-Week Low | $77.60 | $1.00 |
Enterprise Value | $368.53B | $170.07M |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Veritone (VERI) trades at $1.53, up 6.25% in 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $92.19M in 2025 but a net loss of $111.73M, reflecting negative profit margins and ROE. Recent news highlights partnerships with ZeroEyes and the Department of Energy, though a securities class action lawsuit was filed in July 2026 over alleged accounting issues.
The outlook is mixed: analyst consensus leans neutral with 46% buy ratings, but persistent losses and legal risks pose challenges. Upside hinges on AI partnership growth improving profitability, while downside risks include ongoing cash burn and litigation uncertainties. Investors should weigh growth potential against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
